Tolerance to the prolactin-elevating effect of neuroleptics.
Following the rise in serum prolactin at the onset of neuroleptic treatment, patients kept on a constant dose show systematic changes in prolactin during the first 3 months. After 4 months, prolactin reaches a stable level substantially lower than that at the onset of neuroleptic treatment and not differing from that after years of treatment.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D004361:Drug Tolerance; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011346:Prochlorperazine / Q000627:therapeutic use; D011388:Prolactin / Q000097:blood*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D013881:Thioridazine / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D014268:Trifluoperazine; D011388:Prolactin; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine; D004298:Dopamine; D011346:Prochlorperazine